Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Ramsay Sedation Scale is a classic six-level bedside scale ranging from anxious/agitated (1) to no response to stimulus (6). It is commonly used in procedural and critical-care sedation monitoring workflows.
Formula: Ordinal sedation depth scale from 1 (agitated) to 6 (no response).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Observe the patient's level of consciousness and spontaneous behavior without stimulation first. Note whether the patient is awake, eyes open, and whether they are anxious, agitated, or calm. This observation alone determines whether the Ramsay level is 1 or 2.
If the patient appears asleep or unresponsive, apply verbal stimulus first (call patient's name, give a command). If there is no response to voice, apply a standardized physical stimulus — the classic Ramsay assessment uses a glabellar tap (light tap between the eyebrows) or loud auditory stimulus. Assess briskness of response: brisk (4), sluggish (5), or no response (6).
Assign: 1 = anxious/agitated/uncooperative; 2 = cooperative/oriented/tranquil; 3 = responds to verbal commands only (asleep); 4 = brisk response to glabellar tap or loud noise; 5 = sluggish response; 6 = no response. Target Ramsay 2–3 for most mechanically ventilated ICU patients to facilitate weaning. Target Ramsay 4–5 only for specific indications (prone positioning for severe ARDS, refractory elevated ICP, severe status epilepticus).
ICU Physicians & Critical Care Nurses
The Ramsay Scale guides titration of sedative infusions (propofol, dexmedetomidine, midazolam) in mechanically ventilated patients. Target Ramsay 2–3 (light sedation) is associated with shorter mechanical ventilation duration, faster ICU liberation, and lower delirium rates. The scale provides a common language between physicians and nurses for adjusting sedative doses in response to clinical status.
ICU Nurses & Proceduralists
Documents sedation depth during bedside ICU procedures (central line placement, bronchoscopy, tracheostomy). Provides objective pre- and post-procedure sedation depth documentation for medical records and quality review. Ramsay 3–4 is often targeted for comfortable but recoverable procedural sedation in the ICU setting.
Burn Unit Teams
Burn patients require frequent painful dressing changes and procedures. Ramsay Scale guides titration of sedative-analgesic combinations to achieve adequate comfort (Ramsay 3–4) during procedures while maintaining Ramsay 2 between procedures for patient interaction, nutrition, and rehabilitation participation.
Neurology & Neurocritical Care Teams
Refractory status epilepticus requiring general anesthetic agents (propofol, pentobarbital, ketamine) needs deep sedation monitoring. Ramsay 5–6 is sometimes targeted during burst-suppression EEG therapy, with careful monitoring of hemodynamic stability and respiratory function. Ramsay provides a bedside behavioral correlate to complement EEG monitoring.
Risk Management & Quality Teams
Standardized sedation scoring provides objective, time-stamped documentation of sedation depth for medical-legal purposes. In cases of adverse events, documented Ramsay scores demonstrating appropriate sedation monitoring and timely response to deep sedation (5–6) can support quality of care defensibility.
The 2018 PAD/PADIS Guidelines (Devlin et al., Crit Care Med 2018) recommend the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) over the Ramsay Scale for routine ICU sedation assessment. RASS has bidirectional assessment (−5 for unarousable to +4 for combative), superior inter-rater reliability (κ=0.91 vs 0.84 for Ramsay), and better granularity for agitation states. Ramsay's main limitation is that it only has one level for agitation (Level 1), making it less useful for titrating patients in the more common awake-and-agitated clinical scenario.
Light sedation (Ramsay 2 = RASS 0, eyes open and following commands) is strongly associated with improved outcomes versus deep sedation (Ramsay 4–5). The SLEAP and ABC trials demonstrated that light sedation targets reduce mechanical ventilation duration by 2–4 days and ICU length of stay. The default target for most ICU patients should be Ramsay 2–3 unless there is a specific indication for deeper sedation.
The analgesia-first (A1C) approach endorsed by PADIS guidelines recommends assessing and treating pain before adding or increasing sedation. Uncontrolled pain commonly presents as agitation (Ramsay 1). Escalating sedation for pain-driven agitation is ineffective and dangerous — it leads to deeper sedation without addressing the underlying cause. Use CPOT (Critical-Care Pain Observation Tool) or NRS to assess pain first, then treat with opioid or non-opioid analgesia before adjusting sedative dose.
The landmark Kress et al. NEJM 2000 trial demonstrated that daily sedation interruption (DSI) — turning off sedative infusions each morning until the patient is awake — reduces mechanical ventilation duration by 2.4 days and ICU LOS by 3.5 days. DSI should be incorporated into daily sedation management protocols. When sedation is restarted after DSI, begin at half the previous dose and titrate up to the lowest effective dose.
Dexmedetomidine (Precedex), an alpha-2 agonist, produces light sedation (Ramsay 2–3) with patients who remain arousable and cooperative — they can follow commands and participate in weaning. The MENDS and SEDCOM trials demonstrated less delirium with dexmedetomidine vs midazolam. Dexmedetomidine is first-line for mechanically ventilated patients where interaction, early mobility, and delirium prevention are priorities.
The Confusion Assessment Method for the ICU (CAM-ICU) or ICDSC should be performed at every sedation assessment. Delirium is present in 60–80% of mechanically ventilated ICU patients and is independently associated with increased mortality, longer hospitalization, and long-term cognitive impairment. A patient can be Ramsay 2 (cooperative) but delirious — sedation level does not exclude delirium.
Physical and occupational therapy-driven early mobility programs in the ICU are associated with shorter delirium duration, less muscle weakness, and better functional outcomes (ABCDEF Bundle). However, early mobility is only feasible at Ramsay ≤2. Escalating sedation during active rehabilitation protocols directly impedes this goal. Coordinate daily sedation plans with the physical therapy schedule.
Benzodiazepines (lorazepam, midazolam) for ICU sedation are associated with significantly higher rates of delirium, longer mechanical ventilation, and worse long-term cognitive outcomes compared to propofol or dexmedetomidine, based on MENDS2 (Hughes et al., NEJM 2021) and PRODEX (Jakob et al., JAMA 2012). Current PADIS guidelines recommend against benzodiazepine-based sedation for most ICU patients. Reserve benzodiazepines for alcohol withdrawal (CIWA-Ar protocol), seizure management, and specific indications.
Deep sedation (Ramsay 4–5) should be reserved for specific clinical scenarios: severe ARDS requiring prone positioning (typically ≥16 hours per session), refractory intracranial hypertension, severe status epilepticus requiring burst-suppression, specific surgical procedures, or patient-ventilator dyssynchrony refractory to other interventions. Periodically reassess whether the deep sedation indication persists — restart the process of lightening sedation daily.
Propofol has a very rapid onset and offset, making it highly titratable for dynamic clinical situations (procedures, patient transport, rapidly changing clinical status). However, propofol infusion syndrome (PRIS) — metabolic acidosis, cardiac failure, rhabdomyolysis — can occur with doses >67 mcg/kg/min for >48 hours. Monitor triglycerides, CK, and lactate in patients on prolonged or high-dose propofol. The propofol component provides caloric load (1.1 kcal/mL) that must be incorporated into nutrition calculations.
Ramsay Sedation Scale by Ramsay et al. (BMJ 1974). RASS by Sessler et al. (Am J Respir Crit Care Med 2002) demonstrated superior reliability (κ=0.91 vs 0.84 for Ramsay). PAD/PADIS Guidelines (Devlin et al., Crit Care Med 2018) recommend RASS or SAS as primary assessment tools. Daily sedation interruption: Kress et al. (NEJM 2000). MENDS2 trial (Hughes et al., NEJM 2021) and SEDCOM trial (Riker et al., JAMA 2009) for dexmedetomidine vs midazolam/propofol outcomes.
Lower Ramsay levels suggest lighter sedation or agitation, while higher levels indicate progressively deeper sedation with greater airway and respiratory risk.
Use during procedural sedation, postoperative monitoring, and critical-care sedation titration when a simple bedside depth scale is needed.
Ramsay is observer-dependent and less granular for agitation states than some newer scales. It does not independently evaluate delirium, analgesia adequacy, or neurologic injury.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify opioid-related sedation severity (S, 1, 2, 3, 4) and map to common bedside action guidance.
OpenPharmacyCalculate IV infusion rates in mL/hr and drops per minute from volume, time, and drop factor. Essential nursing and pharmacy calculator for safe, accurate IV fluid and medication administration.
OpenPharmacyCalculate morphine milligram equivalents (MME) for opioid medications using CDC conversion factors. ≥50 MME/day warrants caution; ≥90 MME/day carries significantly increased overdose risk.
Open